Table of Contents
ISRN Pharmacology
Volume 2012, Article ID 130347, 7 pages
Research Article

Short-Term Therapy with Rosiglitazone, a PPAR- 𝜸 Agonist, Improves Metabolic Profile and Vascular Function in Nonobese Lean Wistar Rats

1Calderstones School, Harthill Road, Liverpool L18 3HS, UK
2Department of Health Sciences, Liverpool Hope University, Hope Park, Liverpool L16 9JD, UK

Received 19 May 2012; Accepted 21 June 2012

Academic Editors: H. Cerecetto, K. Lutfy, and F. G. M. Russel

Copyright © 2012 Mohammad M. Naderali et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


A number of preclinical and clinical studies have reported blood-pressure-lowering benefits of thiazolidinediones in diabetic subjects and animal models of diabetes. This study was designed to further elucidate vascular effects of rosiglitazone, on healthy nonobese, lean animals. Adult male Wistar rats were randomized and assigned to control and rosiglitazone-treated groups and were dosed daily with either vehicle or rosiglitazone (10 mg kg−1 day−1) by oral gavage for 5 days. Compared with control group, rosiglitazone treatment significantly reduced plasma levels of triglycerides (>240%) and nonesterified free fatty acids (>268%) (both, 𝑃 < 0 . 0 0 1 ). There were no changes in vascular contractility to KCl or noradrenaline between two groups. However, rosiglitazone therapy improved carbamylcholine-induced vasorelaxation ( 9 3 Β± 3 % versus control 7 8 Β± 2 , 𝑃 < 0 . 0 1 ) an effect which was abolished by L-NAME. There was no difference in sodium nitroprusside-induced vasorelaxation between the control and rosiglitazone-treated animals. These results indicate that short-term rosiglitazone therapy improves both metabolic profile and vascular function in lean rats. The vascular effect of rosiglitazone appears to be mediated by alteration in NO production possibly by activation of endothelial PPARγ. This increased NO production together with improved lipid profile may explain mechanism(s) of blood-pressure-lowering effects of thiazolidinediones on both human and experimental animals.